Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where David Cheshire is active.

Publication


Featured researches published by David Cheshire.


Nature Chemical Biology | 2008

Anchored plasticity opens doors for selective inhibitor design in nitric oxide synthase

Elsa D. Garcin; Andrew S. Arvai; Robin J. Rosenfeld; Matt D. Kroeger; Brian R. Crane; Gunilla Andersson; Glen Andrews; Peter Hamley; Philip Mallinder; David Nicholls; Stephen St-Gallay; Alan Tinker; Nigel P. Gensmantel; Antonio Mete; David Cheshire; Stephen Connolly; Dennis J. Stuehr; Anders Åberg; Alan V. Wallace; John A. Tainer; Elizabeth D. Getzoff

Nitric oxide synthase (NOS) enzymes synthesize nitric oxide, a signal for vasodilatation and neurotransmission at low levels, and a defensive cytotoxin at higher levels. The high active-site conservation among all three NOS isozymes hinders the design of selective NOS inhibitors to treat inflammation, arthritis, stroke, septic shock, and cancer. Our structural and mutagenesis results identified an isozyme-specific induced-fit binding mode linking a cascade of conformational changes to a novel specificity pocket. Plasticity of an isozyme-specific triad of distant second- and third-shell residues modulates conformational changes of invariant first-shell residues to determine inhibitor selectivity. To design potent and selective NOS inhibitors, we developed the anchored plasticity approach: anchor an inhibitor core in a conserved binding pocket, then extend rigid bulky substituents towards remote specificity pockets, accessible upon conformational changes of flexible residues. This approach exemplifies general principles for the design of selective enzyme inhibitors that overcome strong active-site conservation.


Journal of Medicinal Chemistry | 2004

2-Aminopyridines as highly selective inducible nitric oxide synthase inhibitors. Differential binding modes dependent on nitrogen substitution

Stephen Connolly; Anders Åberg; Andrew S. Arvai; Haydn G. Beaton; David Cheshire; Anthony Ronald Cook; Sally L. Cooper; David Cox; Peter Hamley; Phil Mallinder; Ian Millichip; David Nicholls; Robin J. Rosenfeld; Stephen St-Gallay; John A. Tainer; and Alan C. Tinker; Alan V. Wallace


Archive | 2001

NOVEL USE OF PHENYLHETEROALKYLAMINE DERIVATIVES

David Cheshire; Stephen Connolly; David AstraZeneca R D Charnwood Cox; Peter AstraZeneca R D Charnwood Hamley; Antonio Mete; Austen Pimm


Archive | 2000

Pyrrolo[3,4-d]pyrimidinone derivatives and their use as medicaments

Martin Cooper; David Cheshire; David Donald; Mark Furber; Matthew Perry; Richard Harrison; Nicholas P Tomkinsson


Archive | 1991

Biologically active amines

Roger Charles Brown; John Dixon; Francis Ince; David Cheshire; Roger Victor Bonnert


Archive | 1998

Pyridine derivatives and pharmaceutical compositions containing them

David Cheshire; David Cladingboel; Simon Hirst; Carol Manners; Michael J. Stocks


Archive | 2004

Sulphonamide compounds that modulate chemokine receptor activity (ccr4)

David Cheshire; Nicholas Kindon; Michael J. Stocks


Archive | 1998

Novel pyridine derivatives and pharmaceutical compositions containing them

David Cheshire; David Cladingboel; Martin Cooper; David Hardern; Simon Hirst; Carol Manners; Michael J. Stocks


Archive | 2005

Thiazolopyramidine compounds for the modulation of chemokine receptor activity

Premji Meghani; David Cheshire; Cherylin Francis Preston; Jeffrey AstraZeneca R D Charnwood Stonehouse


Archive | 2006

Novel n-(fluoro-pyrazinyl)-phenylsulfonamid.es as moodulators of chemokine receptor ccr4.

David Cheshire; Nicholas Kindon; Antonio Mete; Bryan Roberts

Collaboration


Dive into the David Cheshire's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge